

Steven L. Groopman

Partner

New York
646.933.1000 | sgroopman@dicellolevitt.com

485 Lexington Avenue
Suite 1001
New York, New York 10017

Overview

Steven L. Groopman is a partner in DiCello Levitt's Antitrust and Competition Litigation Practice Group and a seasoned class action attorney focused on high-stakes antitrust matters, with substantial experience in the health care sector. Recognized by *Benchmark Litigation, The Legal 500, and Super Lawyers* as a recommended lawyer in antitrust litigation and class actions, Steve represents union health and welfare benefit funds, consumers, small businesses, and other plaintiffs in cases involving complex markets, sophisticated corporate conduct, and significant economic harm.

Steve is known for developing and prosecuting cutting-edge, proprietary cases—often before the issues receive mainstream coverage. He has developed and litigated antitrust matters in a variety of sectors, including health insurance, pharmaceuticals, real estate, and airlines.

Steve is court-appointed Interim Co-Lead Counsel and leads DiCello Levitt's team in *In re CoStar Group Inc., et al., Antitrust Litigation*, a multidistrict litigation challenging CoStar's alleged monopolization of commercial real estate online listing and information services markets. The lawsuit, brought on behalf of commercial real estate brokers and other market participants, alleges that CoStar used its dominant position in platforms including LoopNet and CoStar to restrict customers' ability to work with competitors, lock up customer data, shut out competition, and charge supracompetitive fees.

Steven also leads DiCello Levitt's team in *The Mayor and City Council of Baltimore v. Bausch Health Companies Inc., et al.*, alleging that defendants perpetrated a multifaceted scheme to delay and deter generic competition for the blockbuster IBS drug Xifaxan, including wrongfully listing various patents in the FDA's Orange Book, entering into a reverse payment agreement with the first generic applicant to delay its market entry, and bottlenecking approximately adozen subsequent generic applicants behind the first applicant.

Steve also serves on the Co-Lead Counsel team in *In re Respimat Pharmaceuticals Antitrust Litigation*, a nationwide antitrust class action alleging that the defendants wrongfully listed device patents in the FDA's Orange Book, unlawfully delaying access to affordable generic alternatives for Combivent Respimat and Spiriva Respimat, two essential treatments for chronic obstructive pulmonary disease.

Steve maintains a broad-based practice but has a particular focus on investigating and challenging efforts by major pharmaceutical companies to undermine lower-cost generic and biosimilar competition. Steve also has deep experience in markets affecting homeowners, airline passengers, consumer borrowers, and small businesses. He has previously litigated antitrust and consumer claims involving residential real estate commissions, airline ticket pricing, online payday lending, and unlawful debt collection.

Before joining DiCello Levitt, Steve was a partner in the Boston office of an esteemed class action and complex litigation firm. Earlier in his career, he clerked for the Hon. Dickinson R. Debevoise of the U.S. District Court for the District of New Jersey, practiced at a litigation and white-collar defense boutique in New York, held legal internships focused on human rights and federal litigation, served as a student-attorney in an appellate defender clinic, and worked as a reporter-researcher at *The New Republic*.

Steve has previously been recognized by *Benchmark Litigation* as a Massachusetts Future Star and previously on its 40 & Under list in the plaintiff class action category. He has also been honored by Super Lawyers in the New England/Massachusetts jurisdiction and previously as a Rising Star.

Practice Areas

CLASS ACTION LITIGATION

ANTITRUST AND COMPETITION LITIGATION

Education

George Washington University Law School, J.D. Brown University, A.B., *magna cum laude*

Representative Matters

***In re CoStar Group, Inc., et al., Antitrust Litigation,* No. 3:26-md-03192 (E.D. Va.)**
Steve leads DiCello Levitt's team in a multidistrict antitrust class action challenging CoStar's alleged monopolization of the commercial real estate online listing and information services markets, representing commercial real estate brokers and other market participants who allege they paid supracompetitive fees for CoStar's listing and data products.
Filed: 2026 | **Role:** Interim Co-Lead Counsel

***The Mayor and City Council of Baltimore v. Bausch Health Companies Inc., et al.,* No. 1:26-cv-00667 (D.R.I.)**
Steve leads DiCello Levit's team representing a proposed class of third-party payors alleging that Bausch perpetrated a multifaceted scheme to delay and deter generic competition for its blockbuster drug Xifaxan.
Filed: 2026

***In re Respimat Pharmaceuticals Antitrust Litigation,* No. 25-md-3154 (D. Mass.)**
Steve serves on the Co-Lead Counsel team representing a proposed class of third-party payors alleging that defendant Boehringer Ingelheim perpetrated an anticompetitive scheme to delay and deter generic competition for its multibillion-dollar line of Spiriva Respimat and Combivent Respimat asthma and COPD inhalers.
Filed: 2024

***Sheet Metal Workers' Health Plan of Southern California, Arizona, and Nevada v. AbbVie Inc.,* No. 25-cv-00615 (N.D. Ill.)**
Steve served on the Co-Lead Counsel team representing a proposed class of health plans alleging that AbbVie entered into agreements in restraint of trade with major pharmacy benefit managers to undermine lower-cost biosimilar competition for Humira.
Filed: 2025

***Iron Workers District Council of New England Health and Welfare Fund v. Teva Pharmaceutical Industries Ltd., et al.,* No. 1:23-cv-11131 (D. Mass.)**
Steve served on the Co-Lead Counsel team representing a proposed class of third-party payors alleging that defendant Teva Pharmaceuticals and its affiliates embarked on a decade-long anticompetitive scheme to delay generic competition for QVAR, its blockbuster line of brand-name asthma inhalers.
Filed: 2023 | **Result:** $35 million settlement

***In re American Airlines/JetBlue Antitrust Litigation,* No. 1:22-cv-07374-AMD-TAM (E.D.N.Y.)**
Steve represented a proposed class of airline ticket purchasers alleging that American Airlines and JetBlue entered into an agreement to collude, rather than compete, for customers at four Northeast airports, driving up airline ticket prices.
Filed: 2022

***Solomon, et al. v. American Web Loan Inc., et al.,* No. 17-cv-0145 (E.D. Va.)**
Steve served on the Co-Lead Counsel team representing a proposed class of consumer borrowers alleging that online payday lenders and a private equity firm perpetrated a scheme to issue usurious loans through a Native American tribal entity in violation of RICO, TILA, and state

law.
Filed: 2017 | **Result:** $186 million settlement

***Gingras, et al. v. Rosette, et al.*, No. 15-cv-0101 (D. Vt.)**
Steve served on the Co-Lead Counsel team representing a proposed class of consumer borrowers alleging that online payday lenders, along with a major hedge fund and venture capitalists, perpetrated a scheme to collect unlawful debt in violation of RICO by creating and controlling a Native American tribal entity and issuing usurious loans through that entity in an effort to circumvent state and federal law.
Filed: 2015 | **Result:** $384 million settlement

Awards & Honors

Recommended Lawyer, Antitrust: Civil Litigation/Class Actions—Plaintiff, ***The Legal 500*** (2026)

Future Star, Massachusetts, ***Benchmark Litigation*** (2024-2025)

40 & Under, Plaintiff Class Action, ***Benchmark Litigation*** (2022-2023)

Massachusetts Super Lawyers Honoree, **Super Lawyers** (2023-2025)

New England/Massachusetts Rising Star, **Super Lawyers** (2017-2022)

Publications & Presentations

Publications

"Why Dark Money is Bad Business," *The New York Times*, May 10, 2016

Presentations

"A View from the Courthouse: Lawsuits Targeting PBMs," Coalition of State Rheumatology Organizations, 2017 State Society Advocacy Conference, September 9, 2017

Admissions & Memberships

Bar Admissions

Massachusetts

New York

Court Admissions

U.S. Court of Appeals, Second Circuit

U.S. Court of Appeals, Fourth Circuit

U.S. Court of Appeals, Eighth Circuit

U.S. District Court, District of Massachusetts

U.S. District Court, Eastern District of New York

U.S. District Court, Southern District of New York

Memberships

Corporate Reform Coalition